[The antiviral action of recombinant forms of the human T-lymphocyte CD4 receptor].
A recombinant protein containing the first 179 N-terminus amino acids of human T-lymphocyte CD4-receptor was synthesized in E. coli cells. This recombinant protein was shown to interact with OKT4A and Leu3a monoclonal antibodies competing with HIV gp120 glycoprotein for binding with the native CD4 receptor. Experiments in vitro in human T-lymphocyte cultures showed that the recombinant CD4-protein in concentrations of 1 to 10 micrograms/ml inhibited the virus-induced syncytium formation, HIV replication in cell culture, synthesis of HIV reverse transcriptase and other virus-specific proteins, that is, behaved as a HIV inhibitor.